VivoSeq
Other

Calcinosis

5

Pipeline Programs↗

2

Active Trials↗

3

Companies Involved↗

Calcinosis is an early-stage landscape with 5 programs across 3 companies. The most active players are Hope Pharmaceuticals, Tarsa Therapeutics, Inc., Dawnrays Pharmaceutical (Holdings) Limited. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

29/100

Pipeline Velocity

6/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

25/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

H

Hope Pharmaceuticals

1 program

Phase 2T

Tarsa Therapeutics, Inc.

1 program

Phase 2D

Dawnrays Pharmaceutical (Holdings) Limited

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

8

clinical trials

Recruiting2 · 25%
Unknown status2 · 25%
Completed2 · 25%
Terminated1 · 13%
Withdrawn1 · 13%

Clinical Trials

Trial Activity

8 trials

Intralesional Injection of STS in Treatment of Calcinosis
Recruiting·RRobyn T. Domsic, MD, MPH·Phase 2·NCT06672822·20 enrolled
Quantification of Calcinosis Cutis Disease Burden Using Computed Tomography Images
Recruiting·YYale University·N/A·NCT07228429·56 enrolled
Phase II Study of Calcitonin for Tumoral Calcinosis
Completed·NNational Center for Research Resources (NCRR)·Phase 2·NCT00004358·9 enrolled
Alkaline Citrate Treatment to Lower the Risk of Nephrocalcinosis in Preterm Infants
Completed·UUniversity of Cologne·Phase 3·NCT00249951·80 enrolled
Efficacy of Intralesional Sodium Thiosulfate Versus Intralesional Saline for Dystrophic and Idiopathic Calcinosis Cutis
Terminated·—·Phase 4·NCT03639779·5 enrolled
A Pilot Study to Evaluate Topical Sodium Thiosulfate Therapy for Calcinosis Cutis
Withdrawn·LLoyola University·Phase 2·NCT01918904
Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud Phenomenon
Unknown status·RRoseLab Skin Optics Laboratory·N/A·NCT03972566·5 enrolled
Study to Assess the Efficacy and Safety of Oral Potassium Citrate on the Prevention of Nephrocalcinosis in Extreme Premature
Unknown status·—·Phase 3·NCT01756547·74 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)